- Home
- WYY vs PLRX Comparison
WYY vs PLRX Comparison
Compare WYY & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WYY | PLRX |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.2M | 79.9M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WYY | PLRX |
|---|---|---|
| Price | $4.65 | $1.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $8.67 | $2.67 |
| AVG Volume (30 Days) | 29.1K | ★ 483.3K |
| Earning Date | 03-25-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,545,364.00 | N/A |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $15.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.59 | N/A |
| 52 Week Low | $2.19 | $1.09 |
| 52 Week High | $7.55 | $1.95 |
Technical Indicators
Market Signals| Indicator | WYY | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 39.27 |
| Support Level | $4.13 | $1.12 |
| Resistance Level | $4.99 | $1.36 |
| Average True Range (ATR) | 0.41 | 0.07 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 13.42 | 11.86 |
Price Performance
Historical ComparisonAbout WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.